(Q42177052)

18 October 2017

Vitiligo in a Patient Treated with Interferon Alpha-2a for Behçet's Disease (English)

1 reference

18 October 2017

0 references

1 reference

Gulunay Akcali

2

0 references

author name string

Esra Guney

1

1 reference

18 October 2017

Betul Ilkay Akcay

3

1 reference

18 October 2017

Cihan Unlu

4

1 reference

18 October 2017

Gurkan Erdogan

5

1 reference

18 October 2017

Tahir Kansu Bozkurt

6

1 reference

18 October 2017

Huseyin Bayramlar

7

1 reference

18 October 2017

16 August 2012

1 reference

18 October 2017

Case Reports in Medicine

1 reference

18 October 2017

2012

1 reference

18 October 2017

387140

1 reference

Creative Commons Attribution 3.0 Unported

18 October 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Behçet's disease--a contemporary review

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Vitiligo: auto-immunity and immune responses

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Vitiligo: a manifestation of apoptosis?

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Immune-mediated complications during interferon therapy in hematological patients

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Cutaneous reactions to recombinant cytokine therapy

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Interferons in dermatology.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Interferon-induced vitiligo in hepatitis C patients: a case series.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Therapeutic interventions for vitiligo

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431079

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

17 August 2018

1 reference

12 December 2020

Vitiligo in autoimmune thyroid disease

1 reference

12 December 2020

Behçet's disease and vitiligo in two brothers: coincidence or association?

1 reference

12 December 2020

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

1 reference

12 December 2020

Serum zinc level in vitiligo: a case control study

1 reference

12 December 2020

Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families

1 reference

12 December 2020

Interferon: an inducer of macrophage activation by polyanions

1 reference

12 December 2020

Vitiligo occurring at site of interferon-α 2b injection in a patient with chronic viral hepatitis C: a case report

1 reference

12 December 2020

Results of interferon-alfa therapy in patients with Behçet uveitis

1 reference

12 December 2020

Behçet's syndrome is not associated with vitiligo

1 reference

12 December 2020

Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/387140

1 reference

18 October 2017

1 reference

18 October 2017

1 reference